NASDAQ:ENVB Enveric Biosciences (ENVB) Stock Price, News & Analysis $1.38 +0.01 (+0.36%) Closing price 04:00 PM EasternExtended Trading$1.38 0.00 (0.00%) As of 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Enveric Biosciences Stock (NASDAQ:ENVB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Enveric Biosciences alerts:Sign Up Key Stats Today's Range$1.33▼$1.4250-Day Range$1.28▼$5.3252-Week Range$1.26▼$17.64Volume64,657 shsAverage Volume2.16 million shsMarket Capitalization$5.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations. Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety. In parallel with pharmacology studies, the company is advancing formulation development, toxicology evaluations and analytical methods to support regulatory submissions and clinical trial readiness. The company emphasizes a robust regulatory strategy and plans to file investigational new drug (IND) applications in the United States and Canada. Enveric collaborates with academic institutions, contract research organizations and clinical advisors to validate its drug candidates in emerging psychiatric therapy paradigms, including adjunctive use alongside psychotherapy. Enveric Biosciences trades on the NASDAQ under the ticker ENVB, following a corporate rebranding from FSD Pharma in October 2021 to reflect its exclusive focus on psychedelic medicine. The company is pursuing strategic partnerships and geographic expansion across North America and Europe to accelerate clinical development and future commercialization of its pipeline assets.AI Generated. May Contain Errors. Read More Enveric Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreENVB MarketRank™: Enveric Biosciences scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingEnveric Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageEnveric Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Enveric Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Enveric Biosciences is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enveric Biosciences is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnveric Biosciences has a P/B Ratio of 0.19. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Enveric Biosciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.29% of the float of Enveric Biosciences has been sold short.Short Interest Ratio / Days to CoverEnveric Biosciences has a short interest ratio ("days to cover") of 0.17, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enveric Biosciences has recently increased by 74.29%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnveric Biosciences does not currently pay a dividend.Dividend GrowthEnveric Biosciences does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.18 News SentimentEnveric Biosciences has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Enveric Biosciences this week, compared to 2 articles on an average week.MarketBeat Follows9 people have added Enveric Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 800% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enveric Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders2.41% of the stock of Enveric Biosciences is held by insiders.Percentage Held by Institutions13.82% of the stock of Enveric Biosciences is held by institutions.Read more about Enveric Biosciences' insider trading history. Receive ENVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enveric Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENVB Stock News HeadlinesEnveric Biosciences (NASDAQ:ENVB) Lowered to "Sell" Rating by Wall Street ZenJune 28 at 1:06 AM | americanbankingnews.comEnveric Biosciences (NASDAQ:ENVB) Upgraded to Hold at Wall Street ZenJune 20, 2026 | americanbankingnews.comThe startup growing 23 times faster than NvidiaAn official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes could be the next monster IPO on Wall Street. This company is growing 23 times faster than Nvidia. The Atlantic called it 'the fastest-growing business in the history of capitalism.' It has nothing to do with robots, self-driving cars, or rockets.June 30 at 1:00 AM | Brownstone Research (Ad)Enveric Biosciences Announces Participation in 2026 BIO International ConventionJune 16, 2026 | businesswire.comEnveric Biosciences Releases Updated Investor Presentation MaterialsJune 9, 2026 | tipranks.comEnveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003June 2, 2026 | finance.yahoo.comEnveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003May 19, 2026 | finance.yahoo.comEnveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003May 19, 2026 | businesswire.comSee More Headlines ENVB Stock Analysis - Frequently Asked Questions How have ENVB shares performed this year? Enveric Biosciences' stock was trading at $3.63 at the beginning of 2026. Since then, ENVB shares have decreased by 62.6% and is now trading at $1.3590. How were Enveric Biosciences' earnings last quarter? Enveric Biosciences, Inc. (NASDAQ:ENVB) posted its earnings results on Friday, May, 15th. The company reported ($1.08) earnings per share for the quarter. When did Enveric Biosciences' stock split? Shares of Enveric Biosciences reverse split on the morning of Wednesday, January 29th 2025.The 1-15 reverse split was announced on Tuesday, January 21st 2025. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 28th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Enveric Biosciences? Shares of ENVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enveric Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enveric Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), CrowdStrike (CRWD), Broadcom (AVGO), ServiceNow (NOW) and Adobe (ADBE). Company Calendar Last Earnings5/15/2026Today6/30/2026Next Earnings (Estimated)8/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 ENVB's financial health is in the Yellow zone, according to TradeSmith. ENVB has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENVB CIK890821 Webjaypharma.co Phone(239) 302-1707Fax732-243-9254Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($23.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-220.97% Return on Assets-177.47% Debt Debt-to-Equity RatioN/A Current Ratio11.66 Quick Ratio11.66 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.00 per share Price / Book0.20Miscellaneous Outstanding Shares3,682,000Free Float3,593,000Market Cap$5.08 million OptionableNot Optionable Beta1.12 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ENVB) was last updated on 6/30/2026 by MarketBeat.com Staff. From Our PartnersSMX Could Turn Proof Technology into Major Profit!SMX (Security Matters) PLC embeds invisible molecular markers into plastics, metals, fuels, and textiles — con...Smallcaps Daily | SponsoredThe startup growing 23 times faster than NvidiaAn official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes ...Brownstone Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredGold Is About to Do Something It Hasn’t in 90 YearsThe U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...US Gold Bureau | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredTrump to “roll back” SpaceX IPO?SpaceX surged from a $1.75 trillion IPO valuation to $2.5 trillion in days - but veteran investor Louis Navell...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enveric Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
